Brian O Mahony/X
Apr 24, 2026, 14:29
Brian O Mahony: Clinical Management of Emicizumab and Rebalancing Agents
Brian O Mahony, CEO of Irish Haemophilia Society, former President of WFH and EHC, shared a post on X:
”Young WFH Congress 2026.
Table illustrating switching,bleed management,surgical management and washout periods for Emicizumab and the 3 rebalancing agents.”
Other posts featuring Brian O Mahony on Hemostasis Today.
-
Jun 15, 2026, 15:43Antonio Paul: Donor Safety Is More Than a Sterile Needle
-
Jun 15, 2026, 15:36Alejandro González Veliz: A Coronary Calcium Score of Zero Doesn’t Always Mean Zero Risk
-
Jun 15, 2026, 15:35Tareq Abadl: Your Blood Tells Your Story – Even in the Shape of Its Cells
-
Jun 15, 2026, 15:34Three Days of Learning, Collaboration, and Community at EHC 2026
-
Jun 15, 2026, 15:31Abdul Mannan: What if Our First Move in Acquired Haemophilia A is Costing Frail Patients Time?
-
Jun 15, 2026, 14:11Alba Maiques Diaz: Completion of My Tenure in the YoungEHA Committee at the EHA
-
Jun 15, 2026, 13:51Miguel Gómez Álvarez: Navigating the Complexities of Erythrocytosis and the Role of PIEZO1
-
Jun 15, 2026, 13:37Katja Sockel: EHA 2026 Inspires New Ideas and Global Connections
-
Jun 15, 2026, 13:25Srishti Goyal։ India’s Blood Donation Journey – Looking Beyond the Numbers